Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

A shortage of prescription-strength co-codamol is set to continue until at least June, leaving thousands of chronic pain patients across the UK uncertain about how they will manage daily symptoms. The Scottish government has confirmed limited availability of the strongest 30/500mg tablets, while health boards warn alternative medicines may not fully cover demand.

The shortage is linked to delays in authorization by the Indian government for exporting key codeine-based ingredients needed to manufacture the drug.

Patients Told To Taper Use

Many patients say they first learned of the disruption through calls from local health services. Some have already been advised to slowly reduce their dose to avoid withdrawal symptoms.

Jocelin Harrison, who has relied on the medication for more than three decades after five spinal surgeries, said she was contacted by NHS Lanarkshire and instructed to cut down gradually.

“The only advice I’ve been given so far was to reduce the tablets and try to manage my withdrawal symptoms,” she said, as reported by the BBC.

“I was not offered any other advice or possible replacement pain killers and it’s a great worry for me and other chronic pain sufferers throughout Scotland and the UK.”

Doctors warn that abruptly stopping co-codamol can trigger headaches, nausea, sweating and a sudden increase in pain, particularly for long-term users.

Why Does This Drug Matter So Much?

Co-codamol combines paracetamol with the opioid codeine and is commonly prescribed after surgery or for persistent musculoskeletal conditions. It comes in three strengths: 8mg, 15mg and 30mg of codeine with 500mg paracetamol.

The lowest strength is available over the counter, but the stronger forms require a prescription and are widely used by patients with chronic pain. Because codeine can cause dependence, tapering rather than stopping suddenly is considered essential.

Health boards say supplies of alternative strengths are also limited, making it difficult to simply switch everyone onto another version.

Guidance issued locally states patients, except those undergoing cancer treatment, should gradually reduce usage until stopping completely. No new patients will be started on the medication until supplies stabilize.

What Are The Alternatives?

NHS Grampian has urged pharmacists to prioritize existing stock carefully. However, it stopped short of telling patients to immediately begin cutting back, highlighting variation in local guidance.

Officials acknowledge substitutes exist, but warn they cannot meet the expected rise in demand from patients switching medicines.

Authorities Now Work On Solution

Scotland’s chief pharmaceutical officer Alison Strath said the issue ultimately sits with UK-wide medicine supply systems but confirmed discussions are ongoing.

“Supply issues are expected until June 2026 and we are in regular contact with the UK government to seek assurances they are doing all they can to resolve this,” she said, adding that affected patients will be contacted directly about alternative treatment options.

The UK Department of Health and Social Care said most medicines remain readily available and manufacturers are working to restore production.

The shortage highlights the global nature of generic drug manufacturing. Medicines such as co-codamol 30/500mg are typically produced using ingredients sourced from India and China, meaning regulatory or production delays overseas can quickly affect patients at home.

For now, patients are being urged not to contact GP practices unless advised and to wait for further instructions from their health providers.

Measles Outbreak In UK: A measles outbreak has been confirmed in London's north east area, noted the BMJ. As per the medical journal, the outbreak is among the unvaccinated children. The medical journal also noted that there have been 96 laboratory confirmed cases of measles in England between January 1 to February 9, 2026 and more than a third, which is 34 cases are from Enfield. BMJ also noted that Enfield is also the area with lowest vaccination rates.

As per the data by the UK Health Security Agency or the UKHSA, only 64.3% of 5 year-olds Enfield received both doses of the measles, mumps, and rubella or the MMR vaccine in 2024 and 2025. The majority (74 of 96, 77%) of measles cases confirmed in the UK so far this year were in children aged 10 and under. Some 64% of cases have been in London, 26% in the West Midlands, and 4% in the East Midlands.

Read: Unique Symptoms Of Measles In 2026 And How Long Does The Infection Last?

Measles Outbreak In UK: Previous Cases And How It Made A Comeback

Last month, the World Health Organization revoked the United Kingdom’s measles elimination status after the virus was found to be circulating continuously for over a year.

In 2025, a child in Liverpool died after contracting measles, prompting renewed pressure on the NHS and government to address its return. England recorded 959 laboratory-confirmed cases that year. Although lower than the 2,911 cases in 2024, it still marked the highest annual total since 2012.

Vaccine uptake has steadily declined over the past 12 years. Only 84.4% of children in the UK receive both doses of the MMR vaccine by age five, far below the 95% coverage needed for herd immunity.

Why Has Measles Return To The UK?

In late 2023, measles outbreaks were reported in the UK, which led to a surge in cases in 2024. Vaccination uptake at the end of 2024 was 92% for the first dose, however, for the second dose, it was below 82%.

Dr Vanessa Saliba, consultant epidemiologist at UKHSA said, "Infections can return quickly when childhood vaccine uptake falls - measles elimination is only possible if all eligible children receive two MMRV doses before school. The NHS is making vaccination easier, including offering the second MMRV dose earlier at a new 18-month appointment to boost uptake and support elimination goals."

Read: UK Loses Measles Elimination Status: Why Is This Disease Making A Comeback?

She also noted that children and adults must get vaccinated as NHS also offers catch-up jabs.

Dr Baharat Pankhania, from the University of Exeter, as reported by the BBC said, "Measles is an infection that can be prevented by vaccine - and it's extremely concerning that in the UK we now have pockets of low or no vaccine uptake. We urgently need to remedy this situation." Pankhania also noted that there is a need to make the access to GPs easier, and for an effort that could immunize babies in their homes and counter wrong information around vaccine safety.

The Union Minister of Health and Family Welfare, JP Nadda, today launched two key national initiatives -- the Strategy for Artificial Intelligence in Healthcare for India (SAHI) and the Benchmarking Open Data Platform for Health AI (BODH) to boost the role of AI in the country's healthcare ecosystem.

The initiatives, launched at the India AI Summit at Bharat Mandapam, in the national capital, are aimed at promoting safe, transparent, and accountable AI in healthcare. It will also help strengthen the digital health ecosystem for equitable healthcare access.

What is SAHI and BODH?

SAHI is a national guidance framework to enable the safe, ethical, evidence-based, and inclusive adoption of AI across India’s healthcare system.

It aims to provide strategic direction on governance, data stewardship, validation, deployment, and monitoring of AI solutions, while supporting States and institutions in responsible adoption aligned with public health priorities.

"SAHI is not merely a technology strategy but a governance framework, policy compass, and national roadmap for the responsible use of AI in healthcare,” said Nadda.

He stated that SAHI will guide India in leveraging AI in a manner that is ethical, transparent, accountable, and people-centric. Nadda also emphasized that SAHI provides a structured framework for collaboration, ensuring that innovation flourishes while public interest remains paramount.

The second initiative, BODH, was developed by the Indian Institute of Technology Kanpur in collaboration with the National Health Authority. It is a privacy-preserving benchmarking platform that enables rigorous evaluation of AI models using diverse, real-world health data without sharing underlying datasets.

As a digital public good under the Ayushman Bharat Digital Mission, it is designed to strengthen trust, transparency, and quality assurance in Health AI deployment.

"The collaboration between Government and academia has led to the development of BODH -- the Benchmarking Open Data Platform for Health AI -- which provides a structured mechanism for testing and validating AI solutions before deployment at scale,” said Nadda.

Nadda reiterated that AI solutions must be rigorously evaluated for performance, reliability, and real-world readiness. Together, SAHI and BODH represent India’s commitment to building a trustworthy, inclusive, and globally competitive health AI ecosystem grounded in innovation, responsibility, and public trust.

AI An Indispensable Enabler to Viksit Bharat

Earlier, delivering the keynote address at a session themed “Innovation to Impact: AI as a Public Health Game-Changer”, at the Summit, Anupriya Patel, Union Minister of State for Health and Family Welfare, highlighted AI as an "All-Inclusive Intelligence".

She also emphasized AI's potential in addressing "health inequities across the country".

Patel called technology -- particularly AI "an indispensable enabler" in India's race towards the vision of a Viksit Bharat by 2047.

She highlighted the potential role of AI on India’s vast and diverse population, the rural–urban divide, and the dual burden of communicable and non-communicable diseases, which present unique challenges.

She also noted that AI has been integrated across the entire continuum of healthcare -- from disease surveillance and prevention to diagnosis and treatment.